Barinthus Bio is a clinical-stage biopharmaceutical company developing immunotherapeutic drug candidates for autoimmune and inflammatory diseases using its proprietary SNAP-TI platform, which promotes immune tolerance by guiding T cells to reduce inflammation and restore natural immune non-responsiveness to healthy tissue. The company's lead candidate, VTP-1000, targets celiac disease by restoring immune tolerance to gluten, with additional assets in development for chronic hepatitis B and other indications. As a pre-revenue clinical-stage enterprise, Barinthus Bio does not currently generate product revenues and depends on future regulatory approvals, clinical trial progress, and commercialization to create value for investors.